{"id":"memantine-namenda","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Confusion"},{"rate":"5-10","effect":"Constipation"},{"rate":"2-5","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL807","moleculeType":"Small molecule","molecularWeight":"179.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Memantine selectively blocks NMDA receptor channels in a use-dependent manner, reducing pathological calcium influx caused by chronic glutamate excitotoxicity while preserving normal synaptic transmission. This mechanism is thought to slow neurodegeneration in Alzheimer's disease by protecting neurons from glutamate-mediated damage without completely blocking physiological NMDA receptor function.","oneSentence":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks excessive glutamate signaling in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:17.097Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT07417670","phase":"PHASE4","title":"Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Carnot Laboratories","startDate":"2024-10-04","conditions":"Alzheimer Disease","enrollment":105},{"nctId":"NCT07251023","phase":"PHASE3","title":"Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia","status":"RECRUITING","sponsor":"Bigespas LTD","startDate":"2025-11-20","conditions":"Alzheimer Type Dementia","enrollment":450},{"nctId":"NCT01333865","phase":"PHASE4","title":"A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-01","conditions":"Autism Spectrum Disorders","enrollment":25},{"nctId":"NCT03670095","phase":"PHASE1","title":"Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2018-08-28","conditions":"Healthy","enrollment":64},{"nctId":"NCT03194906","phase":"PHASE2","title":"Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-11-07","conditions":"Glioma of Brain, Craniopharyngioma, Ependymoma","enrollment":34},{"nctId":"NCT02580305","phase":"PHASE2","title":"SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study","status":"COMPLETED","sponsor":"Suven Life Sciences Limited","startDate":"2015-09","conditions":"Alzheimer's Disease","enrollment":564},{"nctId":"NCT00646204","phase":"PHASE4","title":"Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-04","conditions":"Parkinson's Disease","enrollment":40},{"nctId":"NCT03247218","phase":"PHASE2","title":"A Phase - IIa - IIb, Trial to Study the Safety, Tolerability and Efficacy of Memantine as a Long-term Treatment of SCD","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2018-02-02","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT02553928","phase":"PHASE4","title":"Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-10","conditions":"Alzheimer Dementia (AD)","enrollment":62},{"nctId":"NCT03121820","phase":"PHASE1","title":"Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2016-10-11","conditions":"Bioequivalence, AUC, Cmax, Pharmacokinetics","enrollment":18},{"nctId":"NCT00768261","phase":"PHASE4","title":"Corticolimbic Degeneration and Treatment of Dementia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2004-11","conditions":"Dementia","enrollment":39},{"nctId":"NCT02615847","phase":"PHASE2","title":"Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2015-08","conditions":"Sickle Cell Disease","enrollment":9},{"nctId":"NCT02353130","phase":"","title":"Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine Treatment","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-07","conditions":"Autism Spectrum Disorders","enrollment":""},{"nctId":"NCT01392287","phase":"PHASE1","title":"Treatment Resistant Geriatric Depression in Primary Care","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2010-05","conditions":"Major Depressive Disorder","enrollment":12},{"nctId":"NCT01409694","phase":"PHASE3","title":"Alzheimer's Disease - Input of Vitamin D With mEmantine Assay","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2011-09","conditions":"Alzheimer Disease","enrollment":90},{"nctId":"NCT01536314","phase":"PHASE3","title":"Prophylaxis of Neuropathic Pain by mémantine","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2012-02","conditions":"Neuropathic Pain","enrollment":43},{"nctId":"NCT00857649","phase":"PHASE3","title":"Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2003-12","conditions":"Alzheimer's Disease","enrollment":369},{"nctId":"NCT00855686","phase":"PHASE4","title":"Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-01","conditions":"Parkinson's Disease Dementia, Dementia With Lewy Bodies","enrollment":199},{"nctId":"NCT00703430","phase":"NA","title":"Memantine on Aggression and Agitation of Alzheimer's Disease (AD)","status":"UNKNOWN","sponsor":"Peking University","startDate":"2008-03","conditions":"Alzheimer's Disease","enrollment":50},{"nctId":"NCT01696591","phase":"","title":"The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD","status":"UNKNOWN","sponsor":"Duk Lyul Na","startDate":"2012-03","conditions":"Alzheimer Disease, Dementia, Brain Diseases","enrollment":14},{"nctId":"NCT00862940","phase":"PHASE4","title":"A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2005-09","conditions":"Alzheimer's Disease","enrollment":277},{"nctId":"NCT00857233","phase":"PHASE3","title":"Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2004-06","conditions":"Alzheimer's Disease","enrollment":297},{"nctId":"NCT00469456","phase":"PHASE4","title":"Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2007-04","conditions":"Alzheimer's Disease","enrollment":265}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Namenda"],"phase":"marketed","status":"active","brandName":"Memantine (Namenda®)","genericName":"Memantine (Namenda®)","companyName":"Washington University School of Medicine","companyId":"washington-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that blocks excessive glutamate signaling in the brain. Used for Moderate to severe Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}